Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV

NCT02535104 is registered in ClinicalTrials.gov with Tamir Biotechnology, Inc. as lead sponsor.

NCT NCT02535104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02535104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV
Lead sponsor
Tamir Biotechnology, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2016
Completion date
September 30, 2016
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

condylomata acuminata, papillomavirus infections, sexually transmitted diseases